Probi teams with mystery food giant to win EU probiotic health claim

By Shane Starling

- Last updated on GMT

Probi is "reasonably confident" it can win an immunity health claim under the NHCR
Probi is "reasonably confident" it can win an immunity health claim under the NHCR

Related tags Probiotic health claim Respiratory system Irritable bowel syndrome Gut flora European food safety authority

Swedish probiotics supplier Probi has announced an alliance with an unnamed “major multinational” food company that will assist it in its quest to win the first probiotic health claim in the European Union.

“We can’t at this stage say who they are or what the exact arrangement is but they are very much involved in this,” ​chief executive officer Michael Oredsson told NutraIngredients this morning.

‘This’, to begin with, is a clinical trial on the ProbiDefendum strain that is utilised in probiotic juices Friscus/Bravo sold in Sweden, as well as chewable tablets sold in the Nordic region under Probi’s own brand, ProbiFrisk.

That trial will commence at the beginning of 2012 and is due to run for four months, after which it will be added to an article 13.5, proprietary, immune health dossier that will be sent to the European Food Safety Authority (EFSA) for assessment under the EU nutrition and health claims regulation (NHCR) at some point in 2012.

“So there has been a lot of intelligence gathering and we are reasonably confident we have what EFSA wants,”​ Oredsson said, noting the application would be made under the Probi name, with the food giant remaining a silent partner for the foreseeable future.

The planned study

The four-month immunity study will be a placebo-controlled, randomised, double-blind study with at least 300 subjects. Its focus will be the reduction of upper respiratory tract infection symptoms.

Secondary endpoints including the impact of ProbiDefendum versus placebo on a number of immune markers will also be studied.

“EFSA has stated that the combination of data on infections and on immune markers is particularly relevant in the case of immune defence,”​ the company said.

Oredsson said another study was already underway for its LV99 strain testing for irritable bowel syndrome relief in Denmark that was set to conclude before the end of 2011.

He said the regulatory ambiguity surrounding probiotics had not affected the company’s business, where food supplements revenue had grown 114% year on year to Q3 this year. Overall revenue growth was around 30%.

“Outside of Europe there is less health claim concern, especially in the US and Asia.”


The latest knowledge and industrial applications in human microflora including probiotics will be discussed at the MICROBIOTA two-day conference in Paris on December 13-14, 2011. For more information click here.

Related news

Show more

Related products

show more

Innovation in convenient formats: vegan gummies

Innovation in convenient formats: vegan gummies

Content provided by Cambridge Commodities | 05-Mar-2024 | Product Brochure

Supplements and vitamins in pill form have been around for decades, but consumers are now seeking alternatives that fit with their busy lifestyles and...

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Related suppliers

Follow us


View more